Marker Therapeutics (MRKR) Current Leases (2019 - 2023)
Marker Therapeutics (MRKR) posted quarterly Current Leases of $665082.0 for Q1 2023, down 2.76% year-over-year from $683969.0 in Q1 2022, and up 15.23% quarter-over-quarter from $577198.0 in Q4 2022.
Marker Therapeutics (MRKR) Current Leases (2019 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has reported Current Leases for 5 consecutive years, with $665082.0 the latest figure, recorded in Q1 2023.
- In Q1 2023, Current Leases fell 2.76% year-over-year to $665082.0; the TTM figure through Mar 2023 stood at $665082.0 (down 2.76% YoY), while the FY2022 annual figure was $577198.0, down 6.98% from the prior year.
- Current Leases advanced to $665082.0 in Q1 2023 per MRKR's latest filing, from $577198.0 in the prior quarter.
- Across five years, Current Leases topped out at $738389.0 in Q2 2022 and bottomed at $189791.0 in Q1 2019.
- Historically, Current Leases has averaged $441696.5 across 5 years, with a median of $473077.0 in 2021.
- Annual changes were most pronounced in 2020 — Current Leases jumped 134.5% — and 2022, when it decreased 15.67%.
- Marker Therapeutics' Current Leases stood at $204132.0 in 2019, then jumped by 90.46% to $388792.0 in 2020, then surged by 59.59% to $620490.0 in 2021, then retreated by 6.98% to $577198.0 in 2022, then grew by 15.23% to $665082.0 in 2023.
- Business Quant data shows MRKR's Current Leases at $665082.0 in Q1 2023, $577198.0 in Q4 2022, and $490449.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 665,082.00 |
| Dec 31, 2022 | 577,198.00 |
| Sep 30, 2022 | 490,449.00 |
| Jun 30, 2022 | 738,389.00 |
| Mar 31, 2022 | 683,969.00 |
| Dec 31, 2021 | 620,490.00 |
| Sep 30, 2021 | 581,588.00 |
| Jun 30, 2021 | 558,657.00 |
| Mar 31, 2021 | 473,077.00 |
| Dec 31, 2020 | 388,792.00 |
| Sep 30, 2020 | 278,333.00 |
| Jun 30, 2020 | 456,065.00 |
| Mar 31, 2020 | 209,081.00 |
| Dec 31, 2019 | 204,132.00 |
| Sep 30, 2019 | 199,266.00 |
| Jun 30, 2019 | 194,482.00 |
| Mar 31, 2019 | 189,791.00 |